Fiche société
Novartis Pharmaceuticals
Traitements, essais et publications liés.
Traitements113programmes
Essais54liés
Publications72liées
SourceDBlocale
Traitements
113| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 177Lu-DFC413The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors | Cancer | Phase 1 | À vérifier | United States, Canada, Denmark, France, Germany, Israel, Singapore | À vérifier |
| 68Ga-NNS309The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors | Cancer | Phase 1 | À vérifier | United States, Canada, Denmark, France, Germany, Israel, Singapore | À vérifier |
| A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world PracticeThis study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC). This study will use two primary data sources that capture longitudinal, de-identified healthcare utilization derived from claims submitted for reimbursement. | SEP | À vérifier | À vérifier | United States | À vérifier |
| A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following RelapseThe aim of this study was to describe real-world treatment patterns after relapsing on platform disease-modifying therapies (DMTs) in terms of proportions of patients who remain on platform DMTs or escalate to high-efficacy DMTs, as well as time to switching DMTs after relapse. Clinical effectiveness was characterized by comparing treatment failure rates in patients who escalate to high-efficacy DMTs versus those who remain on platform DMTs following initial relapse. | SEP | À vérifier | À vérifier | United States | À vérifier |
| A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple SclerosisThis was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA. | SEP | À vérifier | À vérifier | United States | À vérifier |
| AAA617This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated. | Cancer | Phase 1/2 | À vérifier | United States, Australia, France, Germany, Italy, Japan, Spain | À vérifier |
| AbirateroneThe purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment. | Cancer | Phase 1 | À vérifier | United States, Australia, Canada, Germany, Italy, Japan, South Korea, Spain | À vérifier |
| AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisThis is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses. | SEP | À vérifier | Germany | À vérifier | |
| AMO959The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment. | Cancer | Phase 1/2 | À vérifier | United States, Australia, France, Germany, Italy, Japan, Spain | À vérifier |
| Androgen deprivation therapy (ADT)The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer. | Cancer | Phase 1 | À vérifier | United States, Australia, Canada, Germany, Italy, Japan, South Korea, Spain | À vérifier |
| AnsastrozoleThe purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, … | À vérifier |
| Antiepileptic drug (1 to 3 only)This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures. The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\]. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Colombia, Denmark, France, … | À vérifier |
| AtrasentanA Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN). | Maladie rénale chronique | Phase 3 | À vérifier | United States, China, Colombia, France, Japan, South Korea, Spain, Taiwan | À vérifier |
| CAD106This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease. Patients also had a 2 year follow-up to assess disease progression where no drug was administered. | Alzheimer | Phase 1 | Ralentissement de la progression | Sweden | À vérifier |
| DKB903The purpose of this First-In-Human (FIH), Phase 1, open-label, ascending dose study is to determine safety and tolerability of DKB903, in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE) in order to enable further clinical testing in these populations. | Lupus | Phase 1 | À vérifier | À vérifier | |
| DocetaxelDESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC. | Cancer, Parkinson | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Canada, China, Finland, Greece, Hong Kong, … | À vérifier |
| EAFToS — Characterizing the Use of Ofatumumab in a Real World SettingThis is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes. | SEP | À vérifier | À vérifier | Australia | À vérifier |
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With HypertensionThis study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregates medical information and is constructed mainly from electronic medical record information of general practices, allowing real-time extraction of information entered in medical records, such as prescription status including drug switching and continuation, laboratory values, clinical evaluation scores, and comorbidities, etc. | Hypertension | À vérifier | À vérifier | United States | À vérifier |
| ExemestaneThis phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, … | À vérifier |
| Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfThis is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries. | SEP | À vérifier | À vérifier | United Arab Emirates | À vérifier |
| FingolimodThe purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations. | SEP | Phase 4 | À vérifier | Taiwan | À vérifier |
| GoserelinThe purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, … | À vérifier |
| IanalumabThe purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302). | Lupus | Phase 3 | À vérifier | United States, Brazil, China, Colombia, Czechia, France, Guatemala, Hong Kong, … | À vérifier |
| ianalumab s.c. q12wThis trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, Czechia, … | À vérifier |
| ianalumab s.c. q4wThis trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, Czechia, … | À vérifier |
| inclisiranThis study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome. This pathway includes treatment with inclisiran on top of the standard of care (SOC), which consists of statins with or without ezetimibe, compared to a high-intensity SOC regimen alone (statins +/- ezetimibe). | Maladie coronarienne | Phase 4 | À vérifier | À vérifier | |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLV-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations. | Accident vasculaire cérébral, Maladie coronarienne | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, … | À vérifier |
| INR731The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer. | Cancer | Phase 1 | À vérifier | United States, Australia, Canada, Germany, Italy, Japan, South Korea, Spain | À vérifier |
| IptacopanThe study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region. | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, China, Denmark, France, Germany, … | À vérifier |
| Iptacopan (part 1)The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, China, Colombia, France, Germany, Hong Kong, … | À vérifier |
| Iptacopan (part 2)The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, China, Colombia, France, Germany, Hong Kong, … | À vérifier |
| JDQ443This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination. | Cancer | Phase 3 | United States, Argentina, Australia, Canada, China, Finland, Greece, Hong Kong, … | À vérifier | |
| JSB462This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated. | Cancer | Phase 2 | À vérifier | United States, Australia, Austria, Canada, China, Czechia, France, Germany, … | À vérifier |
| LABA based treatment: indacaterolThis multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully. | SEP | Phase 4 | À vérifier | China | À vérifier |
| LABA/ICS based treatment: budesonide/formoterolThis multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully. | SEP | Phase 4 | À vérifier | China | À vérifier |
| LABA/ICS based treatment: salmeterol/fluticasoneThis multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully. | SEP | Phase 4 | À vérifier | China | À vérifier |
| LAMA based treatment: tiotropiumThis multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully. | SEP | Phase 4 | À vérifier | China | À vérifier |
| LetrozoleThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, … | À vérifier |
| LeuprolideThe purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, … | À vérifier |
| Nilotinib followed by treatment-freeThe main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment | Cancer | Phase 2 | À vérifier | United States, Argentina, Austria, Belgium, Bulgaria, Colombia, Denmark, France, … | À vérifier |
| NIO752Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD) | Alzheimer | Phase 1 | À vérifier | Finland, France, Spain, Sweden | À vérifier |
| Ofatumumab approved doseThis study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Puerto Rico | À vérifier |
| Ofatumumab new doseThis study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Puerto Rico | À vérifier |
| OfatunumabThis study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum. | SEP | Phase 4 | À vérifier | United States, Germany, Italy, Poland, United Kingdom | À vérifier |
| open label RAD001 (only used for post-extension phase)This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures. The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\]. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Colombia, Denmark, France, … | À vérifier |
| Other treatmentThe goal of this observational study is to learn about consequences for the child when the mother is treated with rituximab (or other monoclonal CD-20 antibodies) before or during pregnancy. The main questions it aims to answer are: * Is the infant's immune system effected with lower levels of B-cell markers, higher rates of infections or poor vaccine response? * Are the monoclonal CD20-antibodies fully eliminated in women treated within 6 (12) months prior to conception? Participants will: * At the time of clinical routine blood sampling (at the end of each trimester) the becoming mother will give some additional blood samples for analysis of drug concentration * Within the first year postpartum the child will leave a blood sample to detect antibodies induced by vaccination or infections * Within our routine contacts with the participant (mother) will be asked about infections in both the mother and the child | SEP | Phase 4 | Immunomodulation | China | À vérifier |
| PelacarsenCTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS). | Maladie coronarienne | Phase 3 | À vérifier | À vérifier | |
| Pelacarsen (TQJ230)This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint. | Accident vasculaire cérébral, Maladie coronarienne | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, … | À vérifier |
| QCZ484The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension | Hypertension | Phase 2 | À vérifier | United States, Japan, Singapore | À vérifier |
| RAD001This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures. The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\]. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Colombia, Denmark, France, … | À vérifier |
| rapcabtagene autoleucelThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN). | Lupus | Phase 2 | À vérifier | United States, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, … | À vérifier |
| Remibrutinib (Blinded)A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment. | Myasthénie, SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Georgia, … | À vérifier |
| Remibrutinib (Open Label)A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment. | Myasthénie, SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Georgia, … | À vérifier |
| Remibrutinib oral treatmentThe purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS). | SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, … | À vérifier |
| RibociclibThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, … | À vérifier |
| Risk Perception in Multiple SclerosisThis study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide. | SEP | À vérifier | À vérifier | United States | À vérifier |
| SOCThis study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome. This pathway includes treatment with inclisiran on top of the standard of care (SOC), which consists of statins with or without ezetimibe, compared to a high-intensity SOC regimen alone (statins +/- ezetimibe). | Maladie coronarienne | Phase 4 | À vérifier | À vérifier | |
| theophylline based treatmentThis multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully. | SEP | Phase 4 | À vérifier | China | À vérifier |
| VAY736 1ml PFSThe purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS. | Lupus | Phase 2 | À vérifier | United States, Argentina, Canada, Czechia, Hungary, Italy, Poland, Spain | À vérifier |
| VAY736 2 ml PFSThe purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS. | Lupus | Phase 2 | À vérifier | United States, Argentina, Canada, Czechia, Hungary, Italy, Poland, Spain | À vérifier |
| VAY736 2ml AIThe purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS. | Lupus | Phase 2 | À vérifier | United States, Argentina, Canada, Czechia, Hungary, Italy, Poland, Spain | À vérifier |
| VHB937Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Alzheimer, Sclérose latérale amyotrophique | Phase 2 | Traitement symptomatique | United States, Australia, Canada, China, Czechia, France, Germany, Italy, … | À vérifier |
| YMI024The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L) | Maladie coronarienne | Phase 2 | Immunomodulation | United States, Australia, Germany, Japan, United Kingdom | À vérifier |
| YTB323This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy. | Lupus, Myasthénie | Phase 1/2 | Thérapie cellulaire | Australia, France, Germany, Spain, Switzerland | À vérifier |
| FingolimodThe purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations. | SEP | À vérifier | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, … | À vérifier |
| RAD001This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures. The study consisted of 4 phases for each patient Baseline phase:\[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)\], Core phase \[from randomization at Week 0 (V2) to Week 18 (V11)\], Extension phase \[from Week 18 (V11) until 48 weeks after the last patient had completed the core phase\] and Post Extension phase \[from end of Extension phase to end of study\]. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Canada, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russia, South Korea, … | À vérifier |
| IanalumabThe purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302). | Lupus | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Guatemala, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, … | À vérifier |
| Risk Perception in Multiple SclerosisThis study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide. | SEP | À vérifier | À vérifier | United States | À vérifier |
| FingolimodThe purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations. | SEP | À vérifier | À vérifier | Egypt | À vérifier |
| A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple SclerosisThis was a US-based, observational cross-sectional study with primary data collection via questionnaires directly administered to patients with MS receiving KESIMPTA and care partners of patients with MS (formal or informal)receiving KESIMPTA. | SEP | À vérifier | À vérifier | United States | À vérifier |
| EAFToS — Characterizing the Use of Ofatumumab in a Real World SettingThis is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes. | SEP | À vérifier | À vérifier | Australia | À vérifier |
| CAD106This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease. Patients also had a 2 year follow-up to assess disease progression where no drug was administered. | Alzheimer | Phase 1 | Ralentissement de la progression | Sweden | À vérifier |
| OfatunumabThis study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum. | SEP | Phase 4 | À vérifier | United States, Germany, Italy, Poland, United Kingdom | À vérifier |
| Remibrutinib oral treatmentThe purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS). | SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Italy, Mexico, Portugal, Slovakia, South Africa, Spain, Switzerland, United Kingdom | À vérifier |
| Ofatumumab approved doseThis study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Puerto Rico | À vérifier |
| Nilotinib followed by treatment-freeThe main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment | Cancer | Phase 2 | À vérifier | United States, Argentina, Austria, Belgium, Bulgaria, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Spain, Sweden, United Kingdom | À vérifier |
| IptacopanThe study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region. | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, China, Denmark, France, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Serbia, South Korea, Spain, United Kingdom | À vérifier |
| Remibrutinib (Blinded)A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment. | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Georgia, Germany, India, Italy, Japan, Netherlands, Poland, Romania, Serbia, South Korea, Spain, Taiwan, United Kingdom | À vérifier |
| YTB323This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy. | Myasthénie | Phase 1/2 | Thérapie cellulaire | United States, France, Japan, United Kingdom | À vérifier |
| Iptacopan (part 1)The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. | Lupus | Phase 2 | À vérifier | United States, Argentina, Brazil, China, Colombia, France, Germany, Hong Kong, Hungary, India, Malaysia, Mexico, Philippines, Portugal, Puerto Rico, Singapore, Spain, Turkey (Türkiye), United Kingdom | À vérifier |
| IanalumabThe purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302). | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Guatemala, Hungary, Israel, Japan, Poland, Portugal, Slovakia, South Africa, Spain, Thailand, Turkey (Türkiye) | À vérifier |
| IanalumabThe purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302). | Lupus | Phase 3 | À vérifier | United States, Argentina, Australia, Chile, Colombia, France, Germany, India, Italy, Malaysia, Mexico, Romania, South Korea, Taiwan, United Kingdom | À vérifier |
| VHB937Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | Traitement symptomatique | United States, Australia, Belgium, Canada, China, Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, South Korea, Spain, Sweden, Switzerland, United Kingdom | À vérifier |
| Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfThis is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries. | SEP | À vérifier | À vérifier | United Arab Emirates | À vérifier |
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With HypertensionThis study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data Survey \[JAMDAS\]) owned by M3 Inc. JAMDAS is a database that aggregates medical information and is constructed mainly from electronic medical record information of general practices, allowing real-time extraction of information entered in medical records, such as prescription status including drug switching and continuation, laboratory values, clinical evaluation scores, and comorbidities, etc. | Hypertension | À vérifier | À vérifier | United States | À vérifier |
| A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following RelapseThe aim of this study was to describe real-world treatment patterns after relapsing on platform disease-modifying therapies (DMTs) in terms of proportions of patients who remain on platform DMTs or escalate to high-efficacy DMTs, as well as time to switching DMTs after relapse. Clinical effectiveness was characterized by comparing treatment failure rates in patients who escalate to high-efficacy DMTs versus those who remain on platform DMTs following initial relapse. | SEP | À vérifier | À vérifier | United States | À vérifier |
| AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisThis is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses. | SEP | À vérifier | Germany | À vérifier | |
| Remibrutinib (Blinded)A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment. | SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, … | À vérifier |
| YTB323This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy. | Lupus | Phase 1/2 | Thérapie cellulaire | Australia, France, Germany, Spain, Switzerland | À vérifier |
| IanalumabThe purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302). | Lupus | Phase 3 | À vérifier | United States, Brazil, China, Colombia, Czechia, France, Guatemala, Hong Kong, Hungary, Malaysia, Mexico, Romania, Singapore, South Korea, Spain, Taiwan, Thailand, Vietnam | À vérifier |
| rapcabtagene autoleucelThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN). | Lupus | Phase 2 | À vérifier | United States, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Romania, Saudi Arabia, Singapore, … | À vérifier |
| A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world PracticeThis study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US). Clinical effectiveness will be assessed using annualized relapse rate (ARR), while economic burden will be assessed using healthcare resource utilization (HCRU) and healthcare costs (HCC). This study will use two primary data sources that capture longitudinal, de-identified healthcare utilization derived from claims submitted for reimbursement. | SEP | À vérifier | À vérifier | United States | À vérifier |
| RibociclibThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, Germany, Hong Kong, India, Israel, Mexico, Portugal, Puerto Rico, South Korea, Taiwan, Turkey (Türkiye) | À vérifier |
| NIO752Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD) | Alzheimer | Phase 1 | À vérifier | Finland, France, Spain, Sweden | À vérifier |
| JSB462This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated. | Cancer | Phase 2 | À vérifier | United States, Australia, Austria, Canada, China, Czechia, France, Germany, Israel, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan | À vérifier |
| AMO959The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment. | Cancer | Phase 1/2 | À vérifier | United States, Australia, France, Germany, Italy, Japan, Spain | À vérifier |
| JDQ443This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination. | Cancer | Phase 3 | United States, Argentina, Australia, Canada, China, Finland, Greece, Hong Kong, Hungary, Iceland, India, Italy, Jordan, Lebanon, Malaysia, Mexico, Portugal, Romania, Slovenia, South Korea, … | À vérifier | |
| LABA based treatment: indacaterolThis multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully. | SEP | Phase 4 | À vérifier | China | À vérifier |
| 68Ga-NNS309The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors | Cancer | Phase 1 | À vérifier | United States, Canada, Denmark, France, Germany, Israel, Singapore | À vérifier |
| ianalumab s.c. q4wThis trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Canada, Chile, China, Colombia, Czechia, Estonia, France, Germany, Guatemala, Hong Kong, Hungary, India, Italy, Lithuania, Malaysia, Mexico, Romania, … | À vérifier |
| VAY736 1ml PFSThe purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS. | Lupus | Phase 2 | United States, Argentina, Canada, Czechia, Hungary, Italy, Poland, Spain | À vérifier | |
| YMI024The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L) | Maladie coronarienne | Phase 2 | Immunomodulation | United States, Australia, Germany, Japan, United Kingdom | À vérifier |
| Pelacarsen (TQJ230)This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint. | Accident vasculaire cérébral | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Israel, … | À vérifier |
| PelacarsenCTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS). | Maladie coronarienne | Phase 3 | À vérifier | À vérifier | |
| AtrasentanA Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN). | Maladie rénale chronique | Phase 3 | À vérifier | United States, China, Colombia, France, Japan, South Korea, Spain, Taiwan | À vérifier |
| VHB937This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE). | Alzheimer | Phase 2 | Traitement symptomatique | United States, Australia, Canada, China, Czechia, France, Germany, Italy, Japan, Netherlands, Poland, South Korea, Spain, Sweden, United Kingdom | À vérifier |
| QCZ484The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension | Hypertension | Phase 2 | À vérifier | United States, Japan, Singapore | À vérifier |
| INR731The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer. | Cancer | Phase 1 | À vérifier | United States, Australia, Canada, Germany, Italy, Japan, South Korea, Spain | À vérifier |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLV-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations. | Maladie coronarienne | Phase 4 | À vérifier | United States | À vérifier |
| inclisiranThis study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome. This pathway includes treatment with inclisiran on top of the standard of care (SOC), which consists of statins with or without ezetimibe, compared to a high-intensity SOC regimen alone (statins +/- ezetimibe). | Maladie coronarienne | Phase 4 | À vérifier | À vérifier | |
| DKB903The purpose of this First-In-Human (FIH), Phase 1, open-label, ascending dose study is to determine safety and tolerability of DKB903, in participants with Rheumatoid Arthritis (RA) and participants with Systemic Lupus Erythematosus (SLE) in order to enable further clinical testing in these populations. | Lupus | Phase 1 | À vérifier | À vérifier | |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mLV-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations. | Maladie coronarienne | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Greece, Hong Kong, Hungary, India, Israel, … | À vérifier |
| FingolimodThe purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations. | SEP | Phase 4 | À vérifier | Taiwan | À vérifier |
Essais cliniques
54| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Fingolimod | SEP | Phase 4 | NCT04480853 | SPRING — Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| DKB903 | Lupus | Phase 1 | NCT07923747 | An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) | NOT_YET_RECRUITING |
| inclisiran | Maladie coronarienne | Phase 4 | NCT07684469 | Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia | NOT_YET_RECRUITING |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 4 | NCT06909565 | V-INTERVENTION — Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | RECRUITING |
| INR731 | Cancer | Phase 1 | NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | RECRUITING |
| QCZ484 | Hypertension | Phase 2 | NCT06857955 | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | ACTIVE_NOT_RECRUITING |
| VHB937 | Alzheimer | Phase 2 | NCT07094516 | A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Atrasentan | Maladie rénale chronique | Phase 3 | NCT07498335 | ADVANCE — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | RECRUITING |
| Pelacarsen | Maladie coronarienne | Phase 3 | NCT07625306 | Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL | WITHDRAWN |
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |
| YMI024 | Maladie coronarienne | Phase 2 | NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | RECRUITING |
| VAY736 1ml PFS | Lupus | Phase 2 | NCT06293365 | Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | ACTIVE_NOT_RECRUITING |
| ianalumab s.c. q4w | Lupus | Phase 3 | NCT05126277 | SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| 68Ga-NNS309 | Cancer | Phase 1 | NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | RECRUITING |
| LABA based treatment: indacaterol | SEP | Phase 4 | NCT01794780 | A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator | COMPLETED |
| JDQ443 | Cancer | Phase 3 | NCT05132075 | KontRASt-02 — Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING |
| AMO959 | Cancer | Phase 1/2 | NCT07226986 | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | RECRUITING |
| JSB462 | Cancer | Phase 2 | NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | ACTIVE_NOT_RECRUITING |
| NIO752 | Alzheimer | Phase 1 | NCT05469360 | Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants | ACTIVE_NOT_RECRUITING |
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | SEP | À vérifier | NCT07779460 | A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | RECRUITING |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06675864 | Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT06711887 | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | RECRUITING |
| YTB323 | Lupus | Phase 1/2 | NCT05798117 | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | COMPLETED |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | SEP | À vérifier | NCT05344469 | AIOLOS — A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis | RECRUITING |
| A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse | SEP | À vérifier | NCT07743281 | A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse | COMPLETED |
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension | Hypertension | À vérifier | NCT06604897 | Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension | COMPLETED |
| Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf | SEP | À vérifier | NCT05266469 | Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf | COMPLETED |
| VHB937 | Sclérose latérale amyotrophique | Phase 2 | NCT06643481 | ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05624749 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05639114 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | ACTIVE_NOT_RECRUITING |
| Iptacopan (part 1) | Lupus | Phase 2 | NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | TERMINATED |
| Erenumab | Migraine | Phase 4 | NCT04084314 | APOLLON — Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study | COMPLETED |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06617793 | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| YTB323 | Myasthénie | Phase 1/2 | NCT06704269 | Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Iptacopan | Myasthénie | Phase 3 | NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | ACTIVE_NOT_RECRUITING |
| Nilotinib followed by treatment-free | Cancer | Phase 2 | NCT01784068 | ENESTfreedom — Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients | COMPLETED |
| Ofatumumab approved dose | SEP | Phase 3 | NCT06869785 | FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01892722 | Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ofatunumab | SEP | Phase 4 | NCT06444113 | KATHAROS — Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| CAD106 | Alzheimer | Phase 1 | NCT00411580 | Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD) | COMPLETED |
| EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting | SEP | À vérifier | NCT05090033 | EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting | COMPLETED |
| A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis | SEP | À vérifier | NCT05334472 | A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis | COMPLETED |
| Fingolimod | SEP | À vérifier | NCT05423769 | Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT04676555 | TIMIOS — Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis | COMPLETED |
| Risk Perception in Multiple Sclerosis | SEP | À vérifier | NCT05528666 | Risk Perception in Multiple Sclerosis | COMPLETED |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | SIRIUS-SLE LTE — Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |
| RAD001 | Épilepsie | Phase 3 | NCT01713946 | A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures | COMPLETED |
| Fingolimod | SEP | À vérifier | NCT01285479 | The Gilenya Pregnancy Registry | COMPLETED |
Publications
72| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Androgen deprivation therapy (ADT) | First-in-human evaluation of [F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [Ga]Ga-PSMA-617. | Annals of medicine | ||
| Androgen deprivation therapy (ADT) | 36.25 Gy versus 40 Gy in five fractions of curative stereotactic body radiotherapy for prostate cancer: a propensity score-matched analysis. | Clinical and translational radiation oncology | ||
| rapcabtagene autoleucel | Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy. | Clinica chimica acta; international journal of clinical chemistry | ||
| Antiepileptic drug (1 to 3 only) | Cannabidiolic acid (CBDA) and CBDA-rich extracts modulatory effects on voltage-dependent NaV1.2 sodium channels. | Phytomedicine : international journal of phytotherapy and phytopharmacology | ||
| Antiepileptic drug (1 to 3 only) | Reporting quality and evidence support in randomized controlled trials of Bupleurum-based herbal medicine formulas for epilepsy. | Journal of ethnopharmacology | ||
| Antiepileptic drug (1 to 3 only) | Development and pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol. | Drug delivery | ||
| RAD001 | CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. | Cell death discovery | ||
| VHB937 | petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI. | Alzheimer's research & therapy | ||
| VHB937 | Simulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study. | Revue neurologique | ||
| VHB937 | Defining Alzheimer's disease: stipulations and the ethics of diagnostic change. | Journal of neurology, neurosurgery, and psychiatry | ||
| Iptacopan (part 2) | Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. | Kidney international | ||
| Iptacopan (part 1) | A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria. | Advances in therapy | ||
| Nilotinib followed by treatment-free | Unraveling clinical and biological predictors of successful treatment free remission in Chronic Myeloid Leukemia and its impact on the healthcare system in a low- and middle-income country. | Pakistan journal of medical sciences | ||
| Nilotinib followed by treatment-free | Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML. | Blood advances | ||
| Nilotinib followed by treatment-free | Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study. | Frontiers in pharmacology | ||
| Exemestane | A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor. | Gynecologic oncology | ||
| Exemestane | Exemestane induces neurodevelopmental defects and behavioral diorder in zebrafish embryos by p53 signaling pathway. | Comparative biochemistry and physiology. Toxicology & pharmacology : CBP | ||
| Exemestane | AKR1C3 and CLIC3 mediate the comorbidity of diabetic foot ulcers and hypercholesterolemia via the TGF-β/lipid metabolism axis. | Biochemical and biophysical research communications | ||
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension | Acute myocardial infarction in a patient with HAM/TSP evaluated for circulatory dynamics during mobilization before and after antihypertensive drug modification: a case report. | Journal of medical case reports | ||
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension | Randomized-controlled trial of sacubitril/valsartan and amlodipine combination in Japanese uncontrolled hypertensive patients (J-SAMIT). | Hypertension research : official journal of the Japanese Society of Hypertension | ||
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension | Prescription patterns of sacubitril/valsartan among patients with hypertension in Japan. | Frontiers in cardiovascular medicine | ||
| Docetaxel | Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. | Journal of enzyme inhibition and medicinal chemistry | ||
| Docetaxel | Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective. | Journal of medical economics | ||
| Docetaxel | Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis. | Cancer biology & therapy | ||
| Ofatumumab new dose | Severe autoimmune hepatitis and necrotising pancreatitis following ofatumumab in a patient with multiple sclerosis. | BMJ case reports | ||
| Ofatumumab approved dose | Ofatumumab Treatment Used in Pediatric MOGAD: A Retrospective Case Series. | Journal of central nervous system disease | ||
| Other treatment | On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies. | The Journal of dermatological treatment | ||
| Other treatment | Application of high-intensity focused ultrasound in gynaecological diseases. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | ||
| Other treatment | Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma. | Oncoimmunology | ||
| Risk Perception in Multiple Sclerosis | Narrative analysis and clinical meta-synthesis of YouTube storytelling by men living with multiple sclerosis. | Journal of health psychology | ||
| Fingolimod | Fingolimod induces cytotoxic stress and apoptosis-like cell death in drug-sensitive and P-glycoprotein-overexpressing acute myeloid leukemia cells. | Biochemical and biophysical research communications | ||
| Fingolimod | Investigating FTY720-NF immunomodulation of key lipid, gene, and protein mediators to enhance oral tissue regeneration. | Biomaterials advances | ||
| Iptacopan (part 2) | Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammation. | Inflammopharmacology | ||
| Iptacopan (part 2) | Targeting the Roots of Kidney Disease: Systematic Review of the Therapies Targeting the Complement System. | Medicina (Kaunas, Lithuania) | ||
| Iptacopan (part 1) | The Complement System: An Important New Therapeutic Target in IgA Nephropathy. | Glomerular diseases | ||
| Iptacopan (part 1) | New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases. | Kidney medicine | ||
| Docetaxel | Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial. | Breast (Edinburgh, Scotland) | ||
| Docetaxel | UNCX/SIN3A-Mediated H4K8 decrotonylation suppresses FOXO3 to drive TNBC progression and docetaxel resistance. | Cellular signalling | ||
| Ofatumumab new dose | Case Report of Combined Central and Peripheral Demyelination: Treated With Ofatumumab. | Immunity, inflammation and disease | ||
| Ofatumumab approved dose | Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap. | Clinical pharmacology and therapeutics | ||
| Ofatumumab approved dose | Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD. | CNS drugs | ||
| Remibrutinib oral treatment | Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | ||
| Remibrutinib oral treatment | Emerging synthetic drugs for the management of hidradenitis suppurativa: a comprehensive update. | Expert opinion on pharmacotherapy | ||
| Other treatment | Antitumor Effects of L. subsp. in a Mammary Tumor Model: Regulation of ERα, p53, PCNA, and HIF-1α. | Molecules (Basel, Switzerland) | ||
| Other treatment | Discrepancy Between Eligibility and Practice: A 14-Year Nationwide Study on Curative Resection in Elderly Hepatocellular Carcinoma Patients. | Cancers | ||
| Fingolimod | A tumor microenvironment-responsive calcium overload nanoplatform inducing PANoptosis for enhanced cancer immunotherapy. | Materials today. Bio | ||
| Fingolimod | Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. | Health technology assessment (Winchester, England) | ||
| Antiepileptic drug (1 to 3 only) | Pharmaceutical cocktails in aquatic ecosystems: unveiling the hidden ecotoxicological threats to Microcystis aeruginosa. | Environmental geochemistry and health | ||
| Antiepileptic drug (1 to 3 only) | Parvalbumin interneuron activation rescues both seizures and impaired social novelty in digenic absence epilepsy mice. | Science advances | ||
| CAD106 | Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes. | Alzheimer's & dementia : the journal of the Alzheimer's Association | ||
| CAD106 | Immunotherapeutic approaches for Alzheimer's disease: Exploring active and passive vaccine progress. | Brain research | ||
| Other treatment | Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial. | Therapeutic advances in neurological disorders | ||
| Other treatment | Preferences for Smartphone Versus In-Person Delivery of Contingency Management: A Web-Based Survey of Australians Who Use Methamphetamine. | Drug and alcohol review | ||
| Risk Perception in Multiple Sclerosis | Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. | Lancet (London, England) | ||
| Risk Perception in Multiple Sclerosis | Pressure Ulcer Prevention at Home for People with Long-term Neurological Conditions, Carers and Personal Assistants: Synopsis - a Participatory, Qualitative study (PUP@Home1). | Health and social care delivery research | ||
| Fingolimod | Lymphatic therapies open the valve in Marfan syndrome. | The Journal of clinical investigation | ||
| Fingolimod | Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis. | JAMA neurology | ||
| Fingolimod | FTY720 Increases Doxorubicin Sensitivity in Resistant Acute Myeloid Leukemia Cells. | Journal of visualized experiments : JoVE | ||
| Fingolimod | MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review. | International journal of molecular sciences | ||
| Ianalumab | From Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework. | International journal of molecular sciences | ||
| Antiepileptic drug (1 to 3 only) | Rapid Eye Movement Sleep Suppressing Antidepressant Prescription is Associated with Improved Survival in Amyotrophic Lateral Sclerosis. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | ||
| Fingolimod | IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis. | Cell communication and signaling : CCS | ||
| Fingolimod | Response to "Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims". | Spinal cord | ||
| Fingolimod | Nanoformulated fingolimod for spinal cord injury: promising anti‑neuroinflammatory effects but unsubstantiated bioavailability claims. | Spinal cord | ||
| Ianalumab | Ianalumab plus Eltrombopag in Immune Thrombocytopenia. | The New England journal of medicine | ||
| Ianalumab | Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply. | The New England journal of medicine | ||
| Fingolimod | Fingolimod Acutely Facilitates the Activation of TRKB in a BDNF-dependent Manner. | Cellular and molecular neurobiology | ||
| Antiepileptic drug (1 to 3 only) | TPPU protects against seizures and seizure-associated comorbidities by inhibiting the Akt/mTOR signaling pathway in KA-induced convulsant mice. | Frontiers in immunology | ||
| Antiepileptic drug (1 to 3 only) | Long-Term Inhaled Cannabis Therapy for Chronic Low Back Pain: A Five-Year Retrospective Analysis of Prospectively Collected Patient-Reported Outcomes in 241 Treatment-Refractory Patients. | Biomedicines | ||
| RAD001 | Retraction notice to "Effects of the combination of RAD001 and docetaxel on breast cancer stem cells" [Eur J Cancer 48 (2012) 1581-1592]. | European journal of cancer (Oxford, England : 1990) | ||
| Fingolimod | Effects of Drugs for the Treatment of Multiple Sclerosis in Severe Acute Respiratory Syndrome Coronavirus 2 Infection on the Expression of Angiotensin-converting Enzyme 2 in vitro. | Current neuropharmacology | ||
| Fingolimod | Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion. | Multiple sclerosis (Houndmills, Basingstoke, England) |